Tumor volume reduction rate is superior to RECIST for predicting the pathological response of rectal cancer treated with neoadjuvant chemoradiation: Results from a prospective study
Jian Xiao(Sun Yat-sen University), Jianping Wang(Sun Yat-sen University), Donglin Ren(Sun Yat-sen University), Wenyun Li(National University of Singapore), Junsheng Peng(Guangzhou University of Chinese Medicine), Lei Wang(Sun Yat-sen University), Jian Zheng(Sun Yat-sen University), Yan Huang(Shanghai Pulmonary Hospital), Ping Lan(Sun Yat-sen University), Zhiyang Zhou(Shanghai Jiao Tong University), Jiaying Gong(Sun Yat-sen University), Yuting Tan(Renji Hospital), Yanhong Deng(Sun Yat-sen University)
Cited by 46
Related Papers
Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA
|Clinical Cancer Research|2018|456
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer
|JAMA|2018|410
Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial
|Journal of Clinical Oncology|2019|410
Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial
|Journal of Clinical Oncology|2016|409
BRCA1–BARD1 promotes RAD51-mediated homologous DNA pairing
|Nature|2017|402